Zynerba Pharma (ZYNE) Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome Did Not Achieve Statistical Significance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. HOOD
10. IBM

Go back to Zynerba Pharma (ZYNE) Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome Did Not Achieve Statistical Significance

UPDATE: Needham & Company Downgrades Zynerba Pharmaceuticals (ZYNE) to Hold

July 1, 2020 7:18 AM EDT

(Updated - July 1, 2020 7:22 AM EDT)

(updating comment)

Needham & Company analyst Serge Belanger downgraded Zynerba Pharmaceuticals (NASDAQ: ZYNE) from Buy to Hold.

The analyst comments "Zygel missed primary and secondary endpoints in the pivotal ph 3 CONNECT-FX trial, but met the... More